SUVN-G3031 is primarily investigated for its potential therapeutic applications in the treatment of central nervous system disorders. It shows promise as a selective serotonin receptor antagonist, particularly targeting 5-HT6 receptors, which are implicated in cognitive and mood regulation. Research suggests it may be effective in addressing conditions such as Alzheimer's disease, schizophrenia, and other cognitive impairments. Its ability to modulate serotonin pathways could lead to improved memory, learning, and behavioral outcomes in patients. Clinical trials are ongoing to evaluate its efficacy and safety as a novel treatment option for these neurological and psychiatric conditions.